Top Markets
#1 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +585.95%
#2 Phala Phala +86.06%
#3 Bitway Bitway +35.59%
#4 龙虾 (Lobster) 龙虾 (Lobster) +27.08%
#5 Backpack Backpack +25.83%
#6 ARK ARK +24.61%
#7 Mubarak Mubarak +24.07%
#8 Aerodrome Finance Aerodrome Finance +23.48%
#9 APEX APEX +21.77%
#10 The Black Bull The Black Bull +20.57%
Coin of the day
Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain)
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
शेयरों में रैंक #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
शेयर मूल्य
$0.2483
अंतिम समन्वयन: 2026-07-31
मार्केट कैप
$2.30M
बदलाव (1 दिन)
-3.39%
बदलाव (1 वर्ष)
-89.01%
देश
US
व्यापार Ensysce Biosciences, Inc. (ENSC)

श्रेणी

Healthcare
Ensysce Biosciences, Inc. (ENSC) के लिए EPS
June 2026 TTM तक का EPS: $-2.76
Ensysce Biosciences, Inc. की नवीनतम वित्तीय रिपोर्टों और शेयर मूल्य के अनुसार, कंपनी का वर्तमान EPS (TTM) $-2.76 है। 2023 के अंत में, कंपनी का EPS $-4.69 था, जो 2022 के EPS $-139.44 के की वृद्धि था।
Ensysce Biosciences, Inc. के लिए 2017 से 2026 तक का EPS इतिहास
प्रत्येक वर्ष के अंत में EPS
वर्ष EPS परिवर्तन
2026 (TTM) $-2.76 -39.61%
2024 $-4.57 -2.56%
2023 $-4.69 -96.64%
2022 $-139.44 -60.80%
2021 $-355.68 -63,614.29%
2020 $0.56 133.33%
2019 $0.24 -209.09%
2018 $-0.22 4,130.77%
2017 $-0.01 0.00%
समान कंपनियों या प्रतिस्पर्धियों के लिए EPS
कंपनी EPS EPS अंतर देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -727.54%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 189.13%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -1,105.07%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 91.67%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH